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esponsibility of InstAbstract The present research aimed to improve the dissolution rate and bioavailability of curcumin
using the potential of liquisolid technology. Twelve drug-loaded liquisolid systems (LS-1 to LS-12) were
prepared using different vehicles (PEG 200, PEG 400 and Tween 80) and curcumin concentrations in
vehicle (40%, 50%, 60% and 70%, w/w). The carrier [microcrystalline cellulose (MCC) PH102] to coat
(Aerosils) ratio was 20 in all formulations. The systems were screened for pre-compression properties
before being compressed to liquisolid tablets (LT-1 to LT-12). Post compression tests and in vitro
dissolution of LTs were conducted and the results compared with those obtained for a directly compressed
tablet (DCT) made of curcumin, MCC PH102 and Aerosils. LTs exhibited higher cumulative drug
release (CDR) than the DCT and the optimum formulation, LT-9 (made using Tween 80), was studied by
powder XRD, DSC, SEM and FTIR. Ex-vivo permeation of curcumin from LT-9 through goat
gastrointestinal mucosa was signiﬁcantly (Po0.05) enhanced and its oral bioavailability was increased
18.6-fold in New Zealand rabbits. In vitro cytotoxicity (IC50) of LT-9 towards NCL 87 cancer cells was
40.2 mmol/L substantiating its anticancer efﬁcacy. Accelerated stability studies revealed insigniﬁcant
effects of temperature and humidity on LT-9. In summary, solubility enhancement of curcumin in LTs
produced signiﬁcant improvements in its permeation and bioavailability.
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Liquisolid tablets of curcumin 6011. Introduction
Despite exerting a range of therapeutic effects, curcumin possesses
limited commercial viability due to its poor water solubility and
relatively low bioavailability1. Numerous approaches have been
utilized to overcome these limitations, including reformulation of
curcumin with various oils2, the use of piperine to inhibit its
metabolism3 and the development of vesicular carriers4 and
nanoparticles of curcumin5. Conjugation of curcumin prodrugs
and linkage of curcumin to polyethylene glycol have also been
reported as fruitful approaches. Development of natural and
synthetic curcumin analogs has also been investigated and shown
promising results6.
In spite of its efﬁcacy and safety, curcumin remains to be
approved as a therapeutic agent mainly because of its low
bioavailability7. The reasons for this low bioavailability include
poor absorption, limited tissue distribution and rapid metabolism8–10.
Although curcumin has been reported to be more permeable under
acidic conditions, its permeability cannot be improved by speciﬁc
P-glycoprotein (P-gp) or multi-drug resistance protein (MRP)
inhibitors. However, it can be signiﬁcantly increased through the
use of a curcumin delivery system which reversibly compromises
mucus integrity. Nevertheless, despite intensive research, curcu-
min has not fulﬁlled its pharmacological promise in clinical trials
due to its poor water solubility and extremely low
bioavailability11.
Among various techniques used to improve the dissolution of
poorly soluble drugs, the application of powder solution or
liquisolid technology is one of the most promising techniques.
This is because it is simple, cost effective and commercially
attractive for industrial production. Given that the technique has
never been applied to curcumin, the present research focused on
developing liquisolid tablets of curcumin and assessing their
dissolution characteristics, ability to improve the permeation of
curcumin through the gastrointestinal tract and bioavailability.2. Materials and methods
2.1. Materials
Curcumin (Lot. No. PC/CL/10LOT/09) was kindly supplied by
Natural Remedies Pvt. Ltd. (Bangalore, India). Di-sodium hydro-
gen phosphate, concentrated hydrochloric acid and microcrystal-
line cellulose MCC PH101 and PH102 were purchased from S.D.
Fine Chemical Ltd. (Mumbai, India). Polyethylene glycol 200
(PEG 200) and 400 (PEG 400), glycerol, Tween 80, propylene
glycol and Aerosils were procured from S. Merck (India) Ltd.
HPLC grade methanol and water were purchased from Sigma–
Aldrich Ltd., USA. All other reagents were of analytical grade and
used as received.
2.2. Saturation solubility
Saturation solubility of curcumin was determined by the shake
ﬂask method12. An excess of curcumin was added to 25 mL,
0.1 mol/L HCl, pH 1.2 and 25 mL double distilled water and
shaken for 72 h in a thermostatted water bath (HICONs, Grover
Enterprises, New Delhi, India) at 2572 1C. The resulting suspen-
sions of curcumin were ﬁltered through Whatman 1 ﬁlter paper
and the ﬁltrates centrifuged (Remi Centrifuge, Remi Instruments
Ltd., Vasai, India) at 3000 rpm for 15 min. The supernatants weresuitably diluted and analyzed spectrophotometrically (Shimadzu-
1700, Tokyo, Japan) at 424 nm. The solubilities of curcumin in the
non-volatile solvents glycerin, propylene glycol, PEG 200, PEG
400 and Tween 80 were determined in the same way.2.3. Mathematical design and development of liquisolid systems
In the development of a liquisolid system (LS), the relative
amounts of carrier and coating material that impart acceptable
ﬂow properties and compression characteristics need to be
determined. Knowing the ﬂowable liquid retention potentials of
the carrier (ΦCA) and coat (ΦCO) and the ratio (R) of the amount of
carrier (Q) to coating material (q), the maximum amount of liquid
that can be loaded on a carrier material, i.e. the liquid load factor
(FL), can be calculated using the mathematical model suggested by
Spireas and Bolton13 (Eq. (1)):
FL ¼ΦCA þ ΦCO 1=R
  ð1Þ
Then, based on the drug concentration in the liquid medication,
the weight of drug solution (liquid medication) (W) can be
calculated and used to determine the weight of the carrier (Q)
(Eq. (2)):
FL ¼W=Q ð2Þ
Finally, since
R¼Q=q ð3Þ
the weight of coating (q) can be calculated. As previously
suggested, an R value of 20 was used in this study to provide
admixtures with appropriate properties14-17.2.4. Flowable retention potential (Φ)
The Φ values were determined by ﬁrst determining the angle of
slide (θ). Solvent-powder admixtures with increasing quantities of
non-volatile solvents were prepared and placed individually on one
end of a polished metal plate. This was then gradually uplifted
until the plate makes an angle with the horizontal at which the
admixture is just about to slide. Thereafter, Φ values are calculated
(Eq. (4))
Φ¼Weight of liquid=Weight of solid ð4Þ
and plotted against the corresponding θ values. The Φ value
corresponding to θ¼331 is regarded as the Φ value of the
admixture18. The Φ values were used to formulate the drug
loaded LS.2.5. Interaction studies
Physical mixtures of curcumin with MCC PH102 and Aerosils
were placed in sealed vials and stored for 2 weeks at a temperature
of 5572 1C under 5% moisture19. At the end of the storage
period, samples were collected, mixed with dry KBr powder in a
ratio of 1:9 and subjected to diffuse reﬂectance spectroscopy
(DRS, Shimadzu FTIR-8400, Kyoto, Japan) against a background
of KBr using a scanning range of 500–4000 cm1 and 1 cm1
resolution. The spectra of mixtures were compared with those of
curcumin, MCC PH102 and Aerosils to detect possible
interactions.
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A total of 12 liquisolid systems (LS-1–LS-12) were formulated
using one non-volatile solvent per group of 4 systems [Group I, LS-
1 to 4, PEG 200; Group II, LS-5 to 8, PEG 400; Group III, LS-9 to
12, Tween 80]. MCC PH102 was used as carrier and Aerosils as
coating material in a ratio (R) of 20:1. The Φ values for carrier and
coating were determined and used to calculate FL which, with the
value of W, was used to calculate the values of Q and q (Table 1).
In the primary stage of formulation, MCC PH102 was mixed
with the liquid medication and blended for 2 min in a glass pestle
and mortar to give an even distribution of liquid medication in
MCC PH102. In the secondary stage, the liquid–powder admixture
was spread as a uniform layer on the surface of the mortar and left
for 5 min to allow sufﬁcient adsorption of drug solution to the
surface of the carrier particles. The damp liquid–powder mixture
was converted into a dry and free ﬂowing powder by the gradual
addition of the coating material with continuous blending.
2.7. Pre-compression evaluation
LS-1–LS-12 were evaluated for pre-compression properties; bulk
density, tapped density, compressibility index, angle of repose,
percent cohesivity, Hausner's ratio, percent porosity20,21 and
dispersibility. Cohesivity was determined by placing a weighed
amount of LS on a watch glass and leaving for 15 min to allow it
to adhere. The watch glass was then tilted at an angle of 901 and
the amount retained on the watch glass recorded as cohesivity.
Dispersibility (%) was determined using the method of Gupta et al.
(Eq. (5))22:
Dispersibility %ð Þ ¼ ðWeight powder remaining on watch
glass=Initial weight of sampleÞ  100 ð5Þ
2.8. Preparation of liquisolid tablets
LS were compressed using a hand-operated single punch tablet
press (Jindal Scientiﬁc Industries, Ahmedabad, India) to give aTable 1 Formulation details of liquisolid systems (LS-1 – LS-12), liq
Group
No.
Formulation
code
Drug
(%, w/w)
Ratio, Q/q Non-volatile
solvent, W (mg)
Group-I LS-1 40 20:1 150.0
LS-2 50 20:1 100.0
LS-3 60 20:1 67.75
LS-4 70 20:1 42.85
Group-II LS-5 40 20:1 150.0
LS-6 50 20:1 100.0
LS-7 60 20:1 67.75
LS-8 70 20:1 42.85
Group-III LS-9 40 20:1 150.0
LS-10 50 20:1 100.0
LS-11 60 20:1 67.75
LS-12 70 20:1 42.85
DCT 100 mg 20:1 –
aNonvolatile solvent used: PEG 200 (Group-I; LS-1–LS-4), PEG 400 (Gtotal of 12 liquisolid tablets (LT-1–LT-12). A batch of directly
compressed tablets (DCTs) was also prepared by direct compres-
sion of a blend of curcumin, MCC PH102 and Aerosils (Table 1).2.9. Tablet characteristics
Tablet hardness and friability were determined in triplicate using a
Monsanto hardness tester and Roche0s Friabilator (both from
HICONs, Grover Enterprises, New Delhi, India). To determine
uniformity of weight (mean7standard deviation), 20 tablets were
randomly selected and weighed individually. To determine drug
content, ten tablets from each batch were powdered and extracted
with methanol by vortexing for 10 min. The resulting extracts were
ﬁltered through Whatman 1 ﬁlter paper and the ﬁltrates analyzed
spectrophotometrically. Disintegration time was determined as
detailed in the USP-27/NF 2223.
In vitro dissolution was performed using a USP dissolution
apparatus II. The dissolution medium was 900 mL 0.1 mol/L HCl,
pH 1.2 maintained at 3770.5 1C and stirred at 100 rpm. Aliquots
(5 mL) were withdrawn initially and after 5, 10, 20, 30, 40 and
60 min and replaced with fresh dissolution medium. Samples were
analyzed spectrophotometrically and plots of percent cumulative
drug release (CDR) versus time compared with the dissolution
proﬁle of the DCT of curcumin. Formulations giving high rates of
CDR were selected to undergo powder X-ray diffraction (XRD).2.10. Powder XRD
Powder XRD of curcumin, MCC PH102, Aerosils and LS-1,
5 and 9 was performed using an X-ray diffractometer (Bruker
AXS D8 Advances, Germany). The samples were irradiated by a
Nickel ﬁltered 2.2 Cu-Kα anode, Dermic X-ray tube equipped
with a sample holder with zero background and PMMA & Linux
eye detector. The samples were scanned over a 2θ range of 5–801.
Peak intensities were recorded and the crystallinity index (CI)
calculated using Eq. (6):
CI %ð Þ ¼ ½ðI002–IAMÞ=I002   100 ð6Þuisolid tablets and directly compressed tablets (DCTs) of curcumin.
a
Liquid load
factor, FL
Carrier
material, Q
Coating
material, q
Weight of
tablet (g)
Molecular
fraction
0.27 538.5 26.92 0.815 1.353
0.27 359.1 17.95 0.577 1.082
0.27 239.5 11.97 0.418 0.902
0.27 153.9 7.69 0.304 0.773
0.28 535.7 26.78 0.812 0.992
0.28 357.1 17.85 0.575 0.793
0.28 238.2 11.91 0.416 0.661
0.28 153.0 7.65 0.303 0.566
0.35 425.5 26.78 0.812 0.841
0.35 283.7 17.85 0.498 0.672
0.35 189.2 11.91 0.435 0.560
0.35 121.6 7.65 0.270 0.480
– 100 5 0.205 –
roup-II; LS-5–LS-8), and Tween 80 (Group-III; LS-9–LS-12).
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at 2θ near 181.
2.11. Differential scanning calorimetry (DSC)
DSC thermograms of curcumin, MCC PH102, Aerosils and LS-9
were obtained using a DSC-60 instrument equipped with an intra-
cooler and controlled by TA-60 WS software (Shimadzu, Kyoto,
Japan). Samples were weighed, transferred to hermetically sealed
aluminum pans and heated at a rate of 10 1C/min over a range of
0–300 1C. An indium standard was used to calibrate the instrument
and enthalpy scale. An inert atmosphere was maintained by
purging nitrogen at a rate of 10 mL/min.
2.12. Scanning electron microscopy (SEM)
SEM was performed in order to assess the morphological
characteristics of curcumin, MCC PH102, Aerosils and LS-9.
The sample was mounted on the sample holder with the help of
double sided sticking tape and coated with the layer of gold for 5–
6 min. SEM images were recorded at different magniﬁcations at an
acceleration voltage of 15 kV on a scanning electron microscope
(JEOL 5400, Kyoto, Japan).
2.13. Fourier transform infrared spectroscopy (FTIR)
Samples of curcumin, Tween 80, MCC PH102 and Aerosils were
prepared according to the mathematical model applied to formulate
LS-9, mixed with dry KBr powder in a ratio of 1:9 and examined
by FTIR (Shimadzu FTIR-8400, Kyoto, Japan) using KBR as
background. The scanning range was 4000–400 cm1 with
1 cm1 resolution. The spectra of liquid powder mixtures were
compared with those of curcumin to detect any interactions.
2.14. Ex-vivo gastric permeation
Fresh abomasum from goat stomach was obtained from a local
butcher shop and mucosa prepared by separation of connective
tissue using a scalpel. The prepared sample was mounted over the
receptor compartment of a Franz diffusion cell (internal diameter
2.03 cm) with the dorsal surface facing the donor compartment. A
portion of crushed LT-9 containing 100 mg curcumin was
dispersed in 0.1 mol/L HCl, pH 1.2 and placed in the donor
compartment. The receptor compartment was ﬁlled with 0.1 mol/L
HCl, pH 1.2 and maintained at 3770.5 1C. Aliquots (1 mL) were
withdrawn from the receptor compartment initially and after 5, 10,
15, 20, 30, 40, 60, 100 and 120 min and replaced with equal
volumes of fresh medium. The study was performed in triplicate.
The cumulative amount of drug permeating across the mucosal
membrane (cumulative drug release, CDR) was plotted against
time and compared with the CDR (%) proﬁle of LT-9.
2.15. In vitro cytotoxicity
The cytotoxicity of curcumin and LT-9 to NCL-87 cancer cells
was determined using paclitaxel as control. Aliquots of cell
suspension (5000 cells/100 μL) were seeded into 96-well plates,
incubated for 24 h and then treated with 150 μL curcumin solution
or the equivalent amount of LT-9 for a further 4 h at 37 1C. Finally
the absorbance of each well was determined at 424 nm using a
microplate reader (CLARIOstars High Performance MicroplateReader, BMG Labtech, Offenburg, Germany) with 344 nm as
reference wavelength24. Cell growth inhibition (%) was calculated
using the following equation:
Cell growth inhibition ð%Þ ¼ ð1–WT=WCÞ  100 ð7Þ
where WT denotes the mean number of cancer cells of the treated
group and WC the mean number of cancer cells of the control
group. Data are presented as growth inhibition proﬁles (growth
inhibition as a function of concentration) and IC50 values.
2.16. Pharmacokinetic study
2.16.1. Protocol
The pharmacokinetic study was performed after obtaining
approval from the Institutional Animal Ethics Committee of the
Rajiv Academy for Pharmacy, Mathura, INDIA (IAEC No: IAEC/
RAP/03966). All animal experiments were conducted in full
compliance with ethical and regulatory principles and following
the guidelines of the Association for Assessment and Accreditation
of Laboratory Animal Care. A group of New Zealand rabbits
(n¼8, weight 2–3.5 kg) were divided into two equal groups
designated test (group I) and control (group II). The animals were
fasted overnight prior to drug administration and for a further 4 h
thereafter. Animals received a single oral dose of either LT-9
(group I) or DCT (group II) containing 50 mg of curcumin with
5 mL water. Blood samples (1 mL) were collected using a 3 mL
syringe (Dispo Van, HMD, Faridabad, Haryana, India) from the
marginal ear vein before the dose and at 0.5, 1, 1.5, 2, 4, 6, 8 and
10 h after the dose. Blood samples were transferred into 5 mL
heparinized plastic plasma tubes (13 mm 7.5 mm spray-coated
with 150 USP Units of sodium heparin and with BD hemoguard
closures) (BD & Co., NJ, USA) and plasma separated by
centrifugation at 3500 rpm for 15 min at 8 1C. Plasma samples
were transferred into microcentrifuge tubes and stored at –20 1C
pending analysis.
2.16.2. Curcumin assay
Curcumin plasma concentration was determined using a validated
HPLC assay as reported by Heath et al.25. Chromatography was
performed by isocratic elution on a C18 reversed phase column
(150 mm 3.9 mm, 5 μm, Pierce Chemical Compound, Rockford,
USA) attached to a model LC-CHT 2010 HPLC system (Shi-
madzu, Japan) equipped with an automatic injector (SIL 10A) and
UV detector set at 424 nm. The mobile phase consisted of
acetonitrile:water:methanol:acetic acid (41:36:23:1, v/v/v/v) deliv-
ered at 20 μL/min. The injection volume was 20 μL. A standard
solution of curcumin (100 μg/mL) was prepared by diluting a
stock solution (5 mg in 25 mL methanol) with mobile phase.
Calibration standards of curcumin (0.01, 0.05, 0.1, 0.5, 1.0, 2.5,
5.0 and 10 mg/mL) were prepared by spiking 100 mL aliquots of
blank rabbit plasma with the standard solution. A working solution
of internal standard (4-hydroxybenzophenone) was prepared by
dissolving 5 mg in 1.0 mL methanol and diluting to 25 mL with
mobile phase.
2.16.3. Pharmacokinetic analysis
The maximum plasma concentration (Cmax) and time to reach it
(Tmax) were determined directly from the plasma concentration–time
proﬁles. The area under the plasma concentration–time curve
(AUC) was estimated using the linear trapezoidal method. The
elimination rate constant (ke) and absorption rate constant (ka) were
Vijay Sharma, Kamla Pathak604obtained by linear regression of the log-transformed concentration–
time data of the elimination and absorption phases, respectively. The
absorption half-life (ta1/2) and elimination half-life (t1/2) were
calculated as 0.693/ka and 0.693/ke, respectively. The unpaired
Student's t-test was used to determine differences between calcu-
lated parameters. Differences yielding Po0.05 were considered
statistically signiﬁcant.
2.17. Stability
Accelerated stability testing of LS-9 and LT-9 at 4072 1C and
7575% relative humidity for 3 months was performed in
accordance with ICH Q1A(R2) guidelines. After storage, samples
of LS-9 were evaluated for solid state reversion by determination
of the crystallization index (CI) using powder XRD. Samples of
LT-9 were subjected to in vitro dissolution testing where the
dissolution data of stored samples were compared with those of
fresh LT-9 samples in terms of the similarity (f2) and difference
factor (f1).3. Results and discussion
3.1. Solubility enhancement
The solubility of curcumin was found to be 0.00270.001 mg/mL in
0.1 mol/L HCl, pH 1.2 and 0.00370.001 mg/mL in double distilled
water. This indicates poor solubility of curcumin in both media in
agreement with results reported by other researchers5,26. Results of this
study show application of liquisolid technology can enhance the
solubility of curcumin. This is because the non-volatile solvents
evaluated in the study (glycerine, propylene glycol, PEG 200, PEG
400 and Tween 80) contain polyhydric alcohols capable of forming
hydrogen bonds with the hydroxyl groups (–OH) and hydrogen (–H)
atoms in curcumin. Solubility of curcumin in glycerin
(0.80070.005 mg/mL) and propylene glycol (1.60070.021 mg/mL)
was still relatively low but was greatly increased in Tween 80
(13.5370.42 mg/mL) PEG 400 (9.9270.24 mg/mL) and PEG 200
(8.4170.22 mg/mL). The order of solubility enhancement was:
glycerinopropylene glycoloPEG 200oPEG 400oTween 80.
The fact that the formulation with Tween 80 exhibited the
highest solubility is presumably because polyoxyethylene sorbitan
monooleate contains more –OH groups27 than the other non-
volatile solvents and can form more hydrogen bonds with
curcumin. This was conﬁrmed by FTIR spectroscopy. The fact
that formulations with glycerin and propylene glycol displayed
poor solubility enhancement despite having large numbers of –OH
groups is attributable to their viscous character that impedes the
solubilization process. On the basis of the order of solubility
enhancement, formulations made using PEG 200, PEG 400, and
Tween 80 were selected for further studies.
3.2. Selection of excipients
In order to develop an effective liquisolid formulation, the selection
of carrier and coating material is crucial. The criteria for selection of
the carrier material include good porosity (ability to adsorb/absorb a
large amount of liquid medication), hygroscopicity (ability to
solubilize the drug), ﬂow properties (while retaining the liquid
medication) and compactability (to provide physical strength to the
ﬁnal formulation)28. Similarly, the selection of coating material mustbe based on its ability to cover the wet carrier particles uniformly
and produce a dry-looking powder with free ﬂowing properties
through adsorbing any excess liquid29.
To facilitate selection of carrier and coating materials, the Φ
values of MCC PH101 and PH102 were estimated using the three
non-volatile solvents. MCC PH102 was found to exhibit a higher
Φ value than MCC PH101 (data not shown) consistent with its
higher speciﬁc surface area (SSA) of 1.10 m2/g compared to
1.07 m2/g for MCC PH10130. In addition, MCC PH102 is more
porous than MCC PH101 enabling it to adsorb a larger amount of
liquid31,32. For these reasons, MCC PH102 was selected as the
carrier material in further studies. Simultaneously, Aerosils was
selected as coating material as it was found to possess all the
properties recommended for an efﬁcient coating material.
3.3. Application of mathematical design and formulation
development
The angle of slide was used to determine the Φ values required for
the calculation of FL. Spireas et al.
30 claimed that the angle of slide
is the preferred method to determine the ﬂowability of powders
with particle size o150 μm such as MCC PH102 and Aerosils.
Fig. 1 (A and B) depicts the relationship between the angle of slide
and the corresponding Φ values of MCC PH102 and Aerosils,
respectively. As reported in Table 1, LS with lower drug
concentrations contains relatively more liquid vehicle and require
more carrier material to be adsorbed/absorbed and consequently
more coating material to cover the larger surface area in order to
produce a dry free ﬂowing powder. Such LS requires larger tablets
than those containing higher drug concentrations (Table 1).
The FL value is the maximum amount of liquid that can be
retained by LS to maintain its ﬂowability and compactability. FL
values calculated using Eq. (1)28 are reported in Table 1. In addition,
the physicochemical characteristics of the non-volatile solvent such as
its polarity, viscosity and lipophilicity may also affect the FL value
29.
FL values for PEG 200, PEG 400 and Tween 80 were found to be
0.27, 0.28 and 0.35, respectively. According to Eq. (2), FL is
inversely proportional to the amount of carrier such that smaller
tablets can be achieved if the FL value is high. Utilizing the FL value,
the amounts of carrier and coating material determined by the value
of R were calculated. The higher the R value, the greater the amount
of carrier material and the larger the weight of tablet produced.
3.4. Interaction studies
Interactions between curcumin and MCC PH102 and curcumin
and Aerosils were examined using DRS. The spectrum of
curcumin revealed the presence of both the enolic form (a peak at
3508 cm–1) and ketonic form (the two carbonyl peaks in the range
1730–1659 cm–1). Furthermore, the C¼C stretching vibration at
1601 cm–1and the peak at 1274 cm–1 revealed the presence of the
aromatic alkene group and asymmetric ether group (C–O–C),
respectively (Fig. 2). All these peaks were present in the DRS
spectrum of a binary mixture containing curcumin and MCC
PH102 although some of them were overlapping. However, the
intensity of the stretching vibration at 3508 cm–1 was less than in
the spectrum of curcumin possibly due to hydrogen bonding
between curcumin and MCC PH10233. In the case of the DRS of
the binary mixture of curcumin and Aerosils, peak broadening
was evident in the –OH stretching vibration at 3508 cm–1 and in
the region 1700–1500 cm–1. This again suggests an interaction
Figure 1 Plots showing relationship between the angle of slide (θ) and corresponding Φ values of (A) MCC PH102 and (B) Aerosils.
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ent34. Thus DRS studies indicate the presence of interactions
between curcumin and excipients which are highly desirable in the
development of successful LS of curcumin with increased hydro-
philic characteristics.3.5. Formulation of LS
Determination of Ф values, FL and the quantities of carrier and
coating material based on R¼20 were sequential steps in the
development of LS. Spireas et al.15 reported that release of
methyclothiazide from a liquisolid compact was improved by
increasing the powder excipients R value from 5 to 20 but that no
further improvement occurred even if R was increased to 70.
Similar ﬁndings have been reported by numerous other research-
ers14,16,17. Hence, in this study an R value of 20 was selected. In
addition, the total weight of each individual LS was designed to
incorporate 100 mg curcumin (Table 1).3.6. Pre-compression evaluation of LS
The bulk density (w/v) of the LS was found to be in the range
0.3270.20 to 0.5670.76 (Table 2) whereas the tapped density was
in the range 0.4470.70 to 0.7370.38. In terms of cohesiveness,
ISO Standard 3435 indicates how the angle of repose is a measure
of the cohesiveness of a granular material35. As a characteristic of
the internal friction or cohesion of particles, the angle of repose is
high for a cohesive powder and low for a non-cohesive one. For all
formulations except LS-4, LS-5 and LS-12, the angle of repose was
in the range 22–251 which reﬂects excellent ﬂow properties. The
three exceptions possessed reasonable ﬂow properties that could be
improved by including a glidant. Hausner's ratio and Carr's index of
the LS conﬁrmed good ﬂow properties as all values of the latter
were o25% and of the former o1.2536. As regards dispersibility
which assesses the ability of a powder to ﬂow or pour easily over a
plane, the high values of dispersibility of LS (86.4770.83 to
93.2570.47) assured the ability of the LS to ﬂow.3.7. Post compression parameters of LTs
Generally, a tablet that provides rapid disintegration and drug
dissolution can be produced without applying excessive compres-
sion force37. In this study, sufﬁcient compression force was
applied to produce LTs that did not break during normal handling
and transport but disintegrated and released active drug when
required. Hardness of LTs was in the range 3.070.2 to
3.870.4 kg/cm2 indicating sufﬁcient strength. At the same time,
all LTs passed the friability test with none showing friability41%
by weight (Table 3). The LTs also passed the weight variation
test23 and drug content revealed uniformity ranging from
95.272.2% to 98.271.4%.
Disintegration time ranged from 3.570.3 min for LT-1 to
5.570.4 min for LT-8 (Table 3). The low disintegration
time for LT-1 is indicative of rapid drug release that could
result in rapid onset of action. The disintegration time increased
with increase in drug concentration probably due to the lipophilic
nature of curcumin and resulting decreased wettability of
the LT.
3.8. In-vitro dissolution
The in-vitro dissolution proﬁles (Fig. 3A) of LTs made with Tween
80 (LT-9 to LT-12) displayed the highest CDR of 89.272.0% to
97.372.0% followed in order by those made with PEG400 (LT-5 to
LT-8) of 71.472.0% to 84.173.0% and PEG200 (LT-1 to LT-4) of
61.271.0% to 72.872.0%. This greater ability of Tween 80 to
release curcumin is due to its ability to solubilize more amount of
drug. The dissolution proﬁles exhibited a biphasic release pattern
with an initial fast release phase (CDRR0–20 min) followed by a slow
release phase (CDRR20–60 min). Values of the rate of drug release
over 20 min (CDRR0–20 min) ranged from 5.09 mg/min for LT-4 to
7.58 mg/min for LT-9; values of CDRR20–60 min ranged from
1.10 mg/min for LT-1 to 2.72 mg/min for LT-12 (Table 4). Among
the three groups, the highest CDRs at 60 min were from LT-1, LT-5
and LT-9 with values of 72.2%, 84.1% and 97.3%, respectively.
Given that these three LTs contain the lowest drug concentrations in
Vijay Sharma, Kamla Pathak606the liquid portion, it is clear that increasing the drug concentration in
the liquid portion decreases the release rate. This is presumably
because at higher drug concentration the solubility limit is exceeded,
the fraction of dissolved drug in the non-volatile solvent is decreased
and the release rate is thereby decreased38. Interestingly, a remark-
able difference in the dissolution behavior of curcumin from LTs
was observed when compared to its saturation solubility in the non-
volatile solvents. This indicates that drug release from LTs is not
only dependent on the solubility of the drug in the non-volatile
solvent but also on other factors such as a physical or chemical
interaction between curcumin and the non-volatile solvent.
Reviewing the components of LTs, the role of the carrier
material in the absorption/adsorption of the liquid medication
(solution of curcumin in selected non-volatile solvent) and on
the CDR must be recognized. MCC PH102 is porous, highlyTable 2 Pre-compression evaluation of liquisolid systems (LS-1–LS
Formulation Bulk density
(w/v)
Tapped density
(w/v)
Carr's index Hausner
LS-1 0.32470.20 0.45270.55 11.6570.12 1.1370
LS-2 0.54570.34 0.73170.38 21.4470.22 1.2470
LS-3 0.54570.43 0.69770.44 22.8070.31 1.2370
LS-4 0.55570.76 0.71470.25 22.2670.29 1.2470
LS-5 0.35770.19 0.50070.71 23.6070.32 1.2070
LS-6 0.34870.23 0.45470.40 23.3470.56 1.2270
LS-7 0.32870.83 0.46870.27 24.6470.19 1.2470
LS-8 0.37570.32 0.44570.22 19.8770.70 1.2470
LS-9 0.34070.37 0.44470.25 21.3670.33 1.2170
LS-10 0.34270.37 0.44170.70 21.0870.39 1.2070
LS-11 0.35870.33 0.46570.82 22.9070.24 1.2370
LS-12 0.37570.37 0.47370.78 23.1170.27 1.2370
Figure 2 Diffuse reﬂectance spectra of curcumin, MCC PH102,
Aerosils and their respective binary mixtures for estimation of
compatibility of drug and excipients used.hygroscopic and hydrophilic in nature. Liquid medication is
ﬁrstly adsorbed onto its surface and then absorbed through
available pores resulting in disintegration of the tablet. On
contact with dissolution media, the time taken for LT disin-
tegration varied from 3.570.3 min (LT-1) to 5.570.3 min
(LT-5) with the more rapid disintegration being due to the
faster wetting of the LT and collapse of its structure39,40. Thus
the process of dissolution can be attributed to three mechanisms:
(a) penetration of the dissolution medium through pores of the
carrier material, (b) solubilization of carrier material by the
dissolution medium, and (c) dissolution/diffusion/transfer of
dissolved drug molecules41.
The results of dissolution can be better explained using the
Noyes–Whitney equation:
dC=dt¼DS CS–Cð Þ=h ð8Þ
where dC/dt is the dissolution rate of the drug particles, D is the
diffusion coefﬁcient of the dissolved drug which is dependent on
the viscosity of the dissolution medium, S is the surface area
exposed to dissolution, h is the thickness of the diffusion layer
which is affected by agitation, CS is the saturation solubility of
drug in the diffusion layer and C is the concentration of drug in the
dissolution medium. Since the stirring speed and viscosity of the
dissolution medium are constant, h and D can be assumed to be
constant. This indicates that S and (CS–C) are the factors that
control the dissolution rate of a tablet17.
The drug particles in an LT are dispersed in a hydrophilic non-
volatile solvent which efﬁciently wets the drug particles and
provides a high surface area of drug for dissolution42. When the
LT disintegrates, the primary particles of the LS containing drug in
a state of molecular dispersion are distributed in the dissolution
medium. Accordingly, the higher dissolution rate of an LT may be
attributed to the signiﬁcantly larger surface area of the molecularly
dispersed drug43. In addition, the solubility of the drug (CS) in the
dissolution medium may be increased although this may be limited
by the small amount of liquid vehicle in the LT. Nevertheless, in
the diffusion layer at the solid/liquid interface, it is possible that
the liquid vehicle diffuses with the drug particles away from the
primary liquisolid particles. In this case, the small amount of liquid
vehicle may be sufﬁcient to increase the solubility of drug particles
by acting as a co-solvent with the dissolution medium. As a result,
the concentration gradient (CSC) of the drug and the drug
dissolution rate are increased41,43,44.-12).
's ratio Angle of
repose (1)
Porosity
(%)
Cohesive
index
Dispersibility
(%)
.38 2270.12 24.76 1.570.5 91.8770.67
.44 2370.32 24.20 1.770.2 90.3570.85
.47 2570.15 22.48 1.870.4 88.4570.43
.58 3170.54 22.22 2.170.4 87.8770.25
.61 2470.54 28.57 1.370.2 93.2570.47
.40 2470.34 25.52 1.470.4 90.8570.15
.55 2570.17 23.32 1.770.5 90.1770.37
.49 3270.24 22.43 1.970.2 88.4370.45
.28 2370.24 23.40 1.470.4 91.2570.27
.72 2370.14 23.13 1.570.2 91.0570.55
.28 2470.19 22.99 1.870.5 89.2570.20
.59 3170.46 22.39 2.070.4 86.4770.83
Table 3 Post-compression studies of liquisolid tablets (LT-1–LT-12).
Formulation Hardness (kg/cm2) Friability (%) Weight variation (mg) Drug content (%) Disintegration time (min)
LT-1 3.870.4 0.78 800710 96.5872.65 3.570.3
LT-2 3.270.6 0.72 590712 95.8773.26 3.770.5
LT-3 3.270.4 0.64 430715 95.2472.43 4.570.6
LT-4 3.070.2 0.56 315710 96.0772.59 5.270.2
LT-5 3.270.6 0.22 810710 97.1872.58 4.070.3
LT-6 3.470.4 0.18 580715 95.1872.18 4.270.5
LT-7 3.670.8 0.10 415710 96.0272.43 5.370.2
LT-8 3.470.6 0.07 300705 95.1672.22 5.570.4
LT-9 3.270.8 0.42 800710 96.0271.56 4.570.3
LT-10 3.670.2 0.38 500710 96.1972.18 4.770.8
LT-11 3.070.6 0.37 450705 97.4372.56 5.270.7
LT-12 3.270.4 0.34 270710 98.1871.43 5.470.6
Table 4 Comparative drug release rate (CDRR) in the initial
20 min (CDRR0–20 min) and in the range 20–60 min (CDRR20–60 min)
from liquisolid tablets (LT-1–LT-12).
Formulation CDR
(%) at
20 min
CDRR0–20 min
(mg/min)
CDR
(%) at
60 min
CDRR20–60 min
(mg/min)
LT-1 61.13 6.13 72.18 1.10
LT-2 57.16 5.71 70.11 1.29
LT-3 55.78 5.57 63.13 1.33
LT-4 50.98 5.09 61.16 1.42
LT-5 67.11 6.71 84.12 1.70
LT-6 64.12 6.41 78.19 1.61
LT-7 61.13 6.11 74.87 1.37
LT-8 56.84 5.61 71.38 1.45
LT-9 75.83 7.58 97.34 2.15
LT-10 72.40 7.24 94.12 2.27
LT-11 69.14 6.91 92.31 2.31
LT-12 61.98 6.19 89.18 2.72
DCT 4.65 0.46 20.08 1.54
Liquisolid tablets of curcumin 607The results of solubility determination show that curcumin is
more soluble in Tween 80 (54.1%, w/w), than in PEG 200 (33.6%,
w/w) or PEG 400 (39.7%, w/w). In other words, Tween 80
solubilizes 37.8% more curcumin than PEG 200 and 26.7% more
than PEG 400. These differences must be maintained in the LTs
formulated using these solvents. The in-vitro dissolution data
reveal that formulations with the lowest drug concentration (40%,
w/w) exhibit the highest dissolution which can be best explained
on the basis of saturation solubility. The higher the drug
concentration in an LT the smaller will be the amount of non-
volatile solvent added and the smaller the amount of drug
solubilized in the liquid vehicle. Another explanation is that at
high drug concentration, the drug precipitates the carrier pores and
thereby reduces the rate of drug dissolution18. The potential to
precipitate obviously depends on the solubility of drug in the
solvent and the degree of saturation of the drug solution. However,
it may also depend on a physical interaction between curcumin and
one or more of the carrier, coating material and non-volatile
solvent43,45. Comparative analysis of dissolution proﬁles revealed
that formulations LT-1, LT-5 and LT-9 exhibited the highest CDR
(%) in their respective groups and all displayed higher dissolution
than the DCT (Fig. 3B).
As reported by Abdou46, the rate of drug dissolution
may depend on the physicochemical properties of the
drug including its solubility, crystalline state, state of hydration,
solvation and complexation. In the case of LS, the increase
in surface area of the drug resulting from its adsorption onto the
surface of the carrier plays a signiﬁcant role. This adsorption
possibly converts the drug from a crystalline to an amorphous
state. In order to investigate this, powder XRD studies were carried
out on LS-1, LS-5 and LS-9 as well as on curcumin and
excipients.3.9. Powder XRD
The X-ray diffractogram of curcumin showed sharp, distinct peaks
notably at 2θ angles of 23.11, 24.41 and 25.41 conﬁrming its
crystallinity (Fig. 4). Similarly the diffractogram of MCC PH102
showed a sharp prominent peak at 22.31 also conﬁrming its
crystalline nature. In contrast, a smooth low intensity broad peak
in the diffractogram of Aerosils reﬂected its amorphous nature.
Utilizing the concept of proportionality between the intensity ofpeaks47 and solubility, diffractograms of LS and LTs were
compared in terms of CI values.
The diffractogram of LS-9 did not show a peak at 25.41
(characteristic of curcumin) but did show one at 22.31 (character-
istic of MCC PH102) but with reduced intensity (Fig. 4). This
indicates that curcumin is no longer in a crystalline form in LS-9
and that MCC PH102 is less crystalline probably due to its partial
solubilization in the non-volatile solvent. Similar patterns were
observed for LS-1 and LS-5 also indicating their more amorphous
state. This was further conﬁrmed by CI determinations where the
CI of curcumin of 78.2 was reduced to values of 65.5 (LS-1), 52.6
(LS-5) and 47.8 (LS-9). This conﬁrms that curcumin is molecu-
larly dispersed and that LS systems are more amorphous due to
partial solubilization of MCC PH102 and Aerosils in the non-
volatile solvent.3.10. DSC
The characteristic peak of curcumin at 182.4 1C corresponds to its
melting point (Fig. 5). The thermogram of MCC PH102 displays
Figure 3 In-vitro dissolution proﬁles of (A) all liquisolid tablets (LT-1 to LT-12) and (B) selected formulations (LT-1, LT-5 and LT-9) compared
to that of a directly compressed tablet (DCT) of curcumin.
Figure 4 Powder X-ray diffractograms of curcumin, MCC PH102,
Aerosils, selected liquisolid systems (LS-1, LS-5 and LS-9, fresh
samples) and LS-9 (aged sample).
Figure 5 Differential scanning calorimetry (DSC) thermograms of
curcumin, MCC PH102, Aerosils and LS-9.
Vijay Sharma, Kamla Pathak608two broad endothermic peaks at 98.99 and 264.7 1C corresponding
to volatilization of absorbed water and melting of crystalline
cellulosic material, respectively44. The thermogram of Aerosilsshowed a broad endotherm at 376 1C due to charring and
decomposition of the sample mass. In the thermogram of LS,
the characteristic peak of curcumin was absent conﬁrming its
molecular dispersion in the system. This is consistent with
information provided by McCauley and Brittain (1995)48 indicat-
ing the complete loss of drug thermal features in an amorphous
solid solution. However, a broad endothermic peak over the
temperature range 242–404 1C probably results from the melting
Figure 6 Scanning electron micrographs of (A) curcumin, (B) MCC PH102, (C) Aerosils and (D) LS-9.
Liquisolid tablets of curcumin 609and decomposition of the entire LS. The thermogram of LS-9 is
indicative of a disturbance in the crystalline habit of the
components of the formulation which can be ascribed to a physical
interaction between the excipients during processing. This physical
interaction may be the result of adsorption of liquid drug onto the
surface of MCC PH102. Furthermore, the absence of the char-
acteristic peak of curcumin at 182.4 1C indicates a physical
interaction between drug, carrier material and non-volatile solvent,
validating the results of powder XRD.3.11. SEM
The photomicrograph of curcumin (Fig. 6A) reveals irregular
crystals with a wide particle distribution while that of MCC PH102
(Fig. 6B) shows large elongated slab-like crystals. The photo-
micrograph of Aerosils (Fig. 6C) indicates the presence of
clusters of microﬁbers and a ﬂuffy arrangement. The SEM of
LS-9 (Fig. 6D) reveals particles of MCC PH102 uniformly
covered with Aerosils. The complete absence of curcumin
crystals clearly indicates the drug is completely solubilized in
the non-volatile solvent (Tween 80) and is adsorbed/absorbed onto
the carrier material (MCC PH102). The efﬁciency of Aerosils as a
coating material is also evidenced by its uniform distribution on
the surface of MCC PH102 promoting the retention of non-volatile
solvent to produce an apparently dry free ﬂowing LS. Hence the
ability of LS to hold drug within a powder substrate in a
solubilized form is conﬁrmed.
The mechanism of enhanced dissolution of LT-9 has been
thoroughly discussed but it is important to elucidate the chemicalinteraction at the molecular level. As explained previously, the
non-volatile solvent forms hydrogen bonds with curcumin which
solubilize it and ultimately affects its release. However, drug
release is not solely dependent on enhanced solubility but possibly
involves some degree of chemical interaction. This interaction was
investigated by FTIR analysis of LT-9.3.12. FTIR analysis
The FTIR spectrum of curcumin displays a sharp and prominent
peak in the range 3550–3400 cm–1 reﬂecting the presence of free
–OH groups (Fig. 7A) which are the predominant site for hydrogen
bond formation49. In the presence of Tween 80 and MCC PH102,
the sharp peak at 3508 cm–1 becomes much weaker and is
accompanied by the appearance of a broad band at
3550–3050 cm–1 (Fig. 7B). This is indicative of hydrogen bond
formation34. Furthermore, on addition of Aerosils, the sharp –OH
stretching vibration completely disappears and the broad band
extends over the broader range of 3780–3050 cm–1 (Fig. 7C). This
indicates the replacement of weak hydrogen bonds by stronger ones
on addition of Aerosils50. A similar ﬁnding was reported by
Planinsek et al.51 who investigated the interaction between drug and
excipients and reported that newly formed strong hydrogen bonds
cause cleavage of weaker ones and play an important role in
enhancing drug release from the system. In conclusion, it is
apparent that Tween 80, MCC PH102 and Aerosils all make
positive contributions to enhancing the dissolution of curcumin
from an LT.
Figure 7 FTIR spectra of (A) curcumin, (B) curcumin þ Tween 80
þ MCC PH102 and (C) curcumin þ Tween 80 þ MCC PH102 þ
Aerosils, indicating a positive chemical interaction involving forma-
tion of new hydrogen bonds.
Figure 8 Plots of cumulative drug release (CDR%) and cumulative
drug permeation (CDP %) vs. time proﬁles of LT-9.
Figure 9 In vitro cytotoxicity proﬁles of curcumin, LT-9 and
paclitaxel.
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Any dosage form administered by the oral route must transit the
gastric cavity and later the intestinal region. During this transit, the
drug is exposed to an acidic pH in the stomach followed by a more
alkaline pH in the gastrointestinal tract. As reported previously,
curcumin is insoluble and stable at acidic pH but slightly soluble
and unstable at alkaline pH52. Thus, bioavailability is predicted to
be increased if most of the drug is absorbed from the gastric cavityrather than from the intestine. To investigate whether formulation
in an LT can enhance permeation of curcumin as shown for other
drugs53, an ex vivo permeation study was performed. Since the
gastric transit time is 2 h, the study was designed to estimate drug
permeation within 2 h. The percent cumulative drug permeated
(CDP) was found to be 89.2% with an r20–20min value (coefﬁcient
of regression ranges from 0 to 20 min) of 0.9854 in the initial
phase followed by r220–120 min (coefﬁcient of regression ranges
from 20 to 120 min) of 0.8445 in the later phase. The ex vivo
permeation proﬁle (CDP, %) is compared with the in vitro
dissolution proﬁle of LS-9 (CDR, %) in Fig. 8 where at any
given time the magnitude of release is greater than that of
permeation. This indicates that curcumin effectively permeates
across the gastric mucosa with almost 100% of drug permeating
within 2 h.3.14. In vitro cytotoxicity
Although curcumin is a proven anticancer agent, the objective of
the in vitro cytotoxicity study was to validate the anticancer
activity of a curcumin LT against NCL-87 cancer cells. The
growth inhibition proﬁles (Fig. 9) of curcumin and LT-9 indicate
similar anticancer activity that is much less than that of paclitaxel
(reference) which shows 100% growth inhibition at o10 mmol/L.
The IC50 for paclitaxel of 5.20 mmol/L was signiﬁcantly lower
(Po0.01) than those for curcumin of 32.1 mmol/L and LT-9 of
40.2 mmol/L. This may be attributed to the fact that curcumin has
less ability to reach the cellular cytoplasm. The slightly lower
cytotoxicity of LT-9 than curcumin is presumably due to the
presence of the excipients in the LT54. As previously documented
by Perkin et al.55, IC50r20 mmol/L indicates excellent anticancer
activity while IC50r40 mmol/L reﬂects good anticancer activity.3.15. Pharmacokinetic study
The mean plasma concentration-time proﬁles (Fig. 10) for curcu-
min administered as LT-9 and DCTs to rabbits were analyzed by a
one compartment open model for which data are presented in
Table 5. The curcumin concentration-time proﬁle of LT-9 shows
much higher plasma concentrations than that of DCT at all time
points. Values of Cmax and Tmax for LT-9 were 3.6270.33 mg/mL
Table 5 Comparative pharmacokinetic data for curcumin
administered as DCT and LT-9 formulations.
Parameter Unit DCT LT-9
Cmax mg/mL 0.2470.47 3.6270.33
Tmax h 1.0070.16 2.0070.17
AUC0–10 h mg  h/mL 1.2173.57 22.3572.96
AUC0–1 mg  h/mL 1.2274.62 22.8075.55
FR – 18.6371.026
Ka h
–1 0.5470.00 4.4870.00
Ke h
–1 0.0670.01 0.3370.04
CLT – 0.06  Vd 0.33Vd
t1/2 h 11.1770.15 2.1170.56
Figure 10 Curcumin plasma concentration–time proﬁles of LT-9 and
a directly compressed tablet (DCT).
Liquisolid tablets of curcumin 611and 2.0070.17 h, respectively, compared to 0.2470.47 mg/mL
and 1.0070.16 h, respectively, for DCTs. Thus the curcumin Cmax
was enhanced 15.4-fold by formulation in an LT.
The absorption rate constant (Ka) of curcumin in LT-9 was
enhanced 8.28-fold in comparison to DCT consistent with
enhanced in vivo dissolution of the drug from the LT
(Table 5). As the rate of absorption is a directly related to
bioavailability which in turn depends on the solubility of the
drug, the AUC was predictably higher for LT-9 than for DCT with
values of AUC0–1 of 22.8075.55 and 1.2274.62 μg  h/mL,
respectively. This corresponds to a relative bioavailability of
18.671.0. This pharmacokinetic data support the results of
in vitro studies in showing that the liquisolid technique increases
drug solubility leading to higher dissolution, improved absorption
and enhanced bioavailability. A similar increase in bioavailability
by formulation in an LT was previously established for
famotidine44.
3.16. Stability
Accelerated stability studies of LT-9 and LS-9 were performed to
investigate the effect of storage on physical state and dissolution
behavior. A dissolution study of aged LT-9 samples showedCDR (%) was not signiﬁcantly different from the value for fresh
LT-9 samples indicating dissolution was not affected by stressed
environmental conditions. The similarity factor (f2) of 79 and
difference factor (f1) of 4 conﬁrm no effect of aging on the
performance of LT-9. Powder XRD analysis of aged LS-9 (Fig. 4)
showed small increment in the intensity of the characteristic peaks
of MCC PH102, which may indicate slight crystallization of
dissolved MCC PH102 in the non-volatile solvent. The XRD
pattern was also analyzed for changes in crystallinity of LS-9 by
calculating the CI where the value of 49.2 for aged samples was
not signiﬁcantly different from the value of 47.8 for fresh samples.
In summary, the data show both LS-9 and LT-9 are stable on
storage under stressed conditions.4. Conclusions
This study conﬁrmed that liquisolid technology is a promising
approach to formulate a solid dosage form of curcumin with
enhanced dissolution characteristics. Formulation in a liquisolid
tablet facilitated molecular dispersion of the poorly water-soluble
drug within a hydrophilic carrier matrix that was amenable to
pharmaceutical manufacturing. Determination of in vitro
cytotoxicity established that the anticancer potential of the dosage
form was comparable to that of curcumin. A pharmacokinetic study
in rabbits showed that the enhancement in dissolution due to
replacement of weaker hydrogen bonds by stronger ones resulted
in enhanced bioavailability of curcumin. Stability studies indicated
that the liquisolid tablets were stable even under stressed conditions.
Overall, the developed liquisolid tablet of curcumin has strong
potential for commercialization once its clinical efﬁcacy has been
established.References
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